Alejandra C. Gurtman, M.D.

Vice President
Pfizer

Poster(s):

• (362) Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to Toddlers and Children 6 Months to < 5 Years of Age Who Previously Received Original BNT162b2 as a 3-Dose Primary Series
  Thursday, October 12, 2023

  12:15 PM – 1:30 PM US ET

• (385) Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to 5- to 11-Year-Old Children Who Previously Received 3 Doses of Original BNT162b2
  Thursday, October 12, 2023

  12:15 PM – 1:30 PM US ET

• (1630) Clinical Profile of Acute Respiratory Illness (ARI) Events in the Phase 3 Trial The RSV Vaccine Efficacy Study iN Older Adults Immunized against RSV Disease (RENOIR)
  Friday, October 13, 2023

  12:15 PM – 1:30 PM US ET

• (1632) Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
  Friday, October 13, 2023

  12:15 PM – 1:30 PM US ET

• (1634) Respiratory Syncytial Virus-Associated Health Care Utilization in the Pivotal Phase 3 Trial RSV Vaccine Efficacy Study In Older Adults Immunized Against RSV Disease (RENOIR)
  Friday, October 13, 2023

  12:15 PM – 1:30 PM US ET